The major research objective is to accelerate new therapy - and biomarker development in the field of DED by creating a multidisciplinary European research and training network around DED research.
The scientific part of the project is divided in 3 work packages: Drug discovery (WP1), Preclinical drug development (WP2); and Development of clinical diagnostic tools (WP3). IT-DED3 will handle different therapeutic approaches for DED treatment such as synthesized and upscaled small molecules (serine protease and RIPK1 inhibitors, natural compounds) and will develop innovative drug delivery systems, which will be tested in validated and newly developed in vivo models for DED. For patient stratification, which is highly needed in the field of DED, we will identify new biomarkers and develop innovative imaging techniques in both animal models and in humans.
IT-DED3 constitutes a unique platform for a true translational research dedicated to patients suffering from DED and is able to translate basic research into patient applications (‘bench-to-bedside’ principle).
Overview of the IT-DED3 Research and Training Programme